Gatifloksacin je organsko jedinjenje, koje sadrži 19 atoma ugljenika i ima molekulsku masu od 375,394 Da.[1][2][3][4]

Gatifloksacin
Klinički podaci
Prodajno imeTequin, Zymar
Drugs.comMonografija
Način primeneOftalmički
Farmakokinetički podaci
Poluvreme eliminacije7-14 h
Identifikatori
CAS broj112811-59-3 DaY
ATC kodJ01MA16 (WHO), S01AE06
PubChemCID 5379
DrugBankDB01044 DaY
ChemSpider5186 DaY
KEGGC07661 DaY
ChEBICHEBI:5280 DaY
ChEMBLCHEMBL31 DaY
Hemijski podaci
FormulaC19H22FN3O4
Molarna masa375,394
  • COC1=C2N(C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNC(C)C1)C1CC1
  • InChI=1S/C19H22FN3O4/c1-10-8-22(6-5-21-10)16-14(20)7-12-15(18(16)27-2)23(11-3-4-11)9-13(17(12)24)19(25)26/h7,9-11,21H,3-6,8H2,1-2H3,(H,25,26) DaY
  • Key:XUBOMFCQGDBHNK-UHFFFAOYSA-N ДаY
Fizički podaci
Tačka topljenja182—185 °C (360—365 °F)

Osobine

uredi
Osobina Vrednost
Broj akceptora vodonika 7
Broj donora vodonika 2
Broj rotacionih veza 4
Particioni koeficijent[5] (ALogP) -0,9
Rastvorljivost[6] (logS, log(mol/L)) -2,7
Polarna površina[7] (PSA, Å2) 82,1

Reference

uredi
  1. ^ Park-Wyllie LY, Juurlink DN, Kopp A, Shah BR, Stukel TA, Stumpo C, Dresser L, Low DE, Mamdani MM: Outpatient gatifloxacin therapy and dysglycemia in older adults. N Engl J Med. 2006 Mar 30;354(13):1352-61. Epub 2006 Mar 1. PMID 16510739
  2. ^ Gurwitz JH: Serious adverse drug effects--seeing the trees through the forest. N Engl J Med. 2006 Mar 30;354(13):1413-5. Epub 2006 Mar 1. PMID 16510740
  3. ^ Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS (2011). „DrugBank 3.0: a comprehensive resource for omics research on drugs”. Nucleic Acids Res. 39 (Database issue): D1035—41. PMC 3013709 . PMID 21059682. doi:10.1093/nar/gkq1126.  uredi
  4. ^ David S. Wishart; Craig Knox; An Chi Guo; Dean Cheng; Savita Shrivastava; Dan Tzur; Bijaya Gautam; Murtaza Hassanali (2008). „DrugBank: a knowledgebase for drugs, drug actions and drug targets”. Nucleic acids research. 36 (Database issue): D901—6. PMC 2238889 . PMID 18048412. doi:10.1093/nar/gkm958.  uredi
  5. ^ Ghose, A.K.; Viswanadhan V.N. & Wendoloski, J.J. (1998). „Prediction of Hydrophobic (Lipophilic) Properties of Small Organic Molecules Using Fragment Methods: An Analysis of AlogP and CLogP Methods”. J. Phys. Chem. A. 102: 3762—3772. doi:10.1021/jp980230o. 
  6. ^ Tetko IV, Tanchuk VY, Kasheva TN, Villa AE (2001). „Estimation of Aqueous Solubility of Chemical Compounds Using E-State Indices”. Chem Inf. Comput. Sci. 41: 1488—1493. PMID 11749573. doi:10.1021/ci000392t.  uredi
  7. ^ Ertl P.; Rohde B.; Selzer P. (2000). „Fast calculation of molecular polar surface area as a sum of fragment based contributions and its application to the prediction of drug transport properties”. J. Med. Chem. 43: 3714—3717. PMID 11020286. doi:10.1021/jm000942e.  уреди

Literatura

uredi

Spoljašnje veze

uredi


 Molimo Vas, obratite pažnju na važno upozorenje
u vezi sa temama iz oblasti medicine (zdravlja).